Gilead stock is the publicly traded shares of Gilead Sciences Inc., a biopharmaceutical company that focuses on the development of medicine for diseases. As of 2015, the company's primary focus of research is on medicine to combat AIDS, hepatitis B and hepatitis C.
At the end of the NYSE April 8, 2015, trading day, the average three-month trading volume of Gilead stock is approximately 12,702,200. Gilead Sciences Inc. also has a market cap of $148.75 billion and reported gross profit margins of 84.35 percent. Michael L. Riordan founded the company in 1987. Dr. John C. Martin, Chairman and Chief Executive Officer, has led the company since 1990.